<?xml version="1.0" encoding="UTF-8"?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1" xml:lang="zh" xsi:noNamespaceSchemaLocation="https://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1.xsd"><front><journal-meta><!-- 出版商赋予期刊ID--><journal-id journal-id-type="publisher-id">YIKE</journal-id><journal-title-group><!-- 期刊中文全称--><journal-title>安徽医科大学学报</journal-title><!-- 期刊英文全称--><journal-title xml:lang="en">Acta Universitatis Medicinalis Anhui</journal-title><!-- 期刊英文缩写--><abbrev-journal-title abbrev-type="publisher" xml:lang="en">Acta Universitatis Medicinalis Anhui</abbrev-journal-title><!-- 期刊中文缩写--><abbrev-journal-title abbrev-type="publisher">安徽医科大学学报</abbrev-journal-title></journal-title-group><!-- 期刊ISSN号--><issn pub-type="ppub">1000-1492</issn><!-- 期刊CN号--><issn pub-type="cn">34-1065/R</issn><publisher><!--出版商英文名称【预置实体】 待确认 --><publisher-name xml:lang="en">Anhui Lianzhong Printing Limited Company</publisher-name><!--出版商英文地址【预置实体】 --><publisher-loc xml:lang="en">Editorial Board of Acta Universitatis Medi-cinalis Anhui Meishan Road , Hefei 230032</publisher-loc><!-- 出版商中文名称【预置实体】--><publisher-name>《安徽医科大学学报》编辑部</publisher-name><!--出版商中文地址【预置实体】 --><publisher-loc>安徽省合肥市安徽医科大学校内老图书馆三楼</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="manuscript">25 t486 庞 哲  -1</article-id><article-id pub-id-type="publisher-id">1000–1492（2026）04–0743–06</article-id><article-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.04.020</article-id><article-categories><subj-group subj-group-type="clc"><subject>R692.1</subject></subj-group><subj-group subj-group-type="dc"><subject>A</subject></subj-group><subj-group subj-group-type="heading"><subject>临床医学研究</subject></subj-group></article-categories><title-group><article-title>多囊肾病患者并发尿路感染的病原特征与危险因素分析</article-title><trans-title-group xml:lang="en"><trans-title>Etiological characteristics and risk factors of urinary tract infection in patients with polycystic kidney disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name name-style="eastern"><surname>庞</surname><given-names>哲</given-names></name><name name-style="eastern" xml:lang="en"><surname>Pang</surname><given-names>Zhe</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="author-notes" rid="fna1"/></contrib><contrib contrib-type="author"><name-alternatives><name name-style="eastern"><surname>汪</surname><given-names>靓婧</given-names></name><name name-style="eastern" xml:lang="en"><surname>Wang</surname><given-names>Jingjing</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name name-style="eastern"><surname>李</surname><given-names>大山</given-names></name><name name-style="eastern" xml:lang="en"><surname>Li</surname><given-names>Dashan</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern"><surname>齐</surname><given-names>向明</given-names></name><name name-style="eastern" xml:lang="en"><surname>Qi</surname><given-names>Xiangming</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/><xref ref-type="author-notes" rid="fna2"/></contrib><aff-alternatives id="aff1"><aff><institution>安徽医科大学第一附属医院肾脏内科</institution>，<city>合肥</city>  <postal-code>230022</postal-code></aff><aff xml:lang="en"><institution>Dept of Nephrology， The First Affiliated Hospital of Anhui Medical University， Hefei</institution>　<postal-code>230022</postal-code></aff></aff-alternatives></contrib-group><author-notes><corresp xml:lang="en" id="cor1"><named-content content-type="corresp-name">Qi Xiangming</named-content>， E-mail： <email>qxm119@126.com</email></corresp><fn fn-type="other" specific-use="about-author" id="fna1"><p><named-content content-type="corresp-name">庞哲</named-content>，男，硕士研究生；</p></fn><fn fn-type="other" specific-use="about-author" id="fna2"><p><named-content content-type="corresp-name">齐向明</named-content>，男，博士，副教授，博士生导师，通信作者，E-mail： <email>qxm119@126.com</email></p></fn></author-notes><pub-date pub-type="epub" iso-8601-date="2026-03-10T09：14：58"><day>10</day><month>03</month><year>2026</year></pub-date><pub-date pub-type="ppub"><day>23</day><month>04</month><year>2026</year></pub-date><volume>61</volume><issue>4</issue><fpage>743</fpage><lpage>747</lpage><page-range>743-747</page-range>  <history><date date-type="received">        <day>01</day><month>03</month><year>2026</year></date></history><abstract abstract-type="key-points"><sec><title>目的</title><p>分析常染色体显性遗传性多囊肾病（ADPKD）合并尿路感染的病原学特点及危险因素。</p></sec><sec><title>方法</title><p>回顾性分析肾脏内科收治的244例ADPKD患者，根据有无合并尿路感染分为研究组（138例）与对照组（106例），研究组患者均进行病原学检查与药敏试验，收集两组患者的临床资料，明确ADPKD合并尿路感染的危险因素。</p></sec><sec><title>结果</title><p>研究组138例，共检出105株病原体，其中，革兰染色阴性菌79株，革兰染色阳性菌20株，真菌6株。大肠埃希菌对氨苄西林、哌拉西林、环丙沙星等抗生素耐药率较高；粪肠球菌对四环素耐药率较高。研究组与对照组在性别、尿路感染既往史、C反应蛋白、尿红细胞、尿白细胞增多、中性粒细胞百分比、血钠、血钙、总胆固醇、血清铁、转铁饱和度方面存在统计学差异（<italic>P</italic>&lt;0.05），多因素二元Logistic回归分析发现ADPKD患者的女性（<italic>OR</italic>=2.236，<italic>P</italic>=0.004）、有尿路感染既往史（<italic>OR</italic>=2.383，<italic>P</italic>=0.002）、尿白细胞增多（<italic>OR</italic>=2.726，<italic>P</italic>=0.001）、中性粒细胞百分比升高（<italic>OR</italic>=1.040，<italic>P</italic>=0.010）、C反应蛋白升高（<italic>OR</italic>=1.011，<italic>P</italic>=0.007）与血钙升高（<italic>OR</italic>=4.389，<italic>P</italic>=0.024）是发生尿路感染的危险因素（<italic>P</italic>&lt;0.05）。</p></sec><sec><title>结论</title><p>ADPKD患者合并尿路感染病原菌以革兰染色阴性菌为主，女性、尿路感染既往史、尿白细胞增多、中性粒细胞百分比升高、C反应蛋白升高与血钙升高是引发尿路感染的危险因素。</p></sec></abstract><trans-abstract abstract-type="key-points" xml:lang="en"><sec><title>Objective</title><p>To analyze the etiological characteristics and risk factors of autosomal dominant polycystic kidney disease （ADPKD） complicated with urinary tract infection （UTI）.</p></sec><sec><title>Methods</title><p>A retrospective analysis was performed on 244 patients with ADPKD admitted to the Department of Nephrology. The patients were stratified into a study group （<italic>n</italic>=138） and a control group （<italic>n</italic>=106） according to the presence or absence of concurrent UTI. All patients in the study group underwent etiological testing and drug susceptibility testing. Clinical data of both groups were collected to identify the risk factors for ADPKD complicated with UTI.</p></sec><sec><title>Results</title><p>A total of 105 pathogens were detected in 138 cases in the study group， including 79 Gram-negative bacteria， 20 Gram-positive bacteria and 6 fungi. <italic>Escherichia coli</italic> showed a relatively high resistance rate to ampicillin， piperacillin and ciprofloxacin. <italic>Enterococcus faecalis</italic> had a relatively high resistance rate to tetracycline. There were statistically significant differences between the study group and the control group in terms of gender， history of urinary tract infection， C-reactive protein （CRP）， increased urine red blood cells， increased urine white blood cells， increased percentage of neutrophils， blood sodium， blood calcium， total cholesterol， serum iron and transferrin saturation （<italic>P</italic>&lt;0.05）. Multivariate binary Logistic regression analysis revealed that female gender （<italic>OR</italic>=2.236， <italic>P</italic>=0.004）， history of urinary tract infection （<italic>OR</italic>=2.383， <italic>P=</italic>0.002）， increased urine white blood cells （<italic>OR</italic>=2.726， <italic>P=</italic>0.001）， increased percentage of neutrophils （<italic>OR</italic>=1.040， <italic>P=</italic>0.010）， elevated C-reactive protein （<italic>OR</italic>=1.011， <italic>P</italic>=0.007） and elevated blood calcium （<italic>OR</italic>=4.389， <italic>P=</italic>0.024） were risk factors of urinary tract infection in ADPKD patients （<italic>P</italic>&lt;0.05）.</p></sec><sec><title>Conclusion</title><p>The main pathogens of UTI in patients with ADPKD are Gram-negative bacteria. Female， previous history of urinary tract infection， urinary leukocytosis， increased percentage of neutrophils， increased CRP and increased serum calcium are risk factors of UTI.</p></sec></trans-abstract><kwd-group kwd-group-type="author"><kwd>常染色体显性多囊肾病</kwd><kwd>肾功能损伤</kwd><kwd>尿路感染</kwd><kwd>细菌感染</kwd><kwd>病原学特点</kwd><kwd>危险因素</kwd></kwd-group><kwd-group xml:lang="en" kwd-group-type="author"><kwd>autosomal dominant polycystic kidney disease</kwd><kwd>renal dysfunction</kwd><kwd>urinary tract infection</kwd><kwd>bacterial infection</kwd><kwd>etiological characteristics</kwd><kwd>risk factors</kwd></kwd-group><funding-group><award-group><funding-source>安徽省自然科学基金项目</funding-source><award-id>1908085MH245</award-id></award-group><funding-statement>安徽省自然科学基金项目（编号：1908085MH245）</funding-statement></funding-group><funding-group xml:lang="en"><award-group><funding-source>Fund program  Natural Science Foundation of Anhui Province</funding-source><award-id>1908085MH245</award-id></award-group><funding-statement>Natural Science Foundation of Anhui Province （No. 1908085MH245）</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="4"/><equation-count count="0"/><ref-count count="11"/><page-count count="5"/><word-count count="14309"/></counts><custom-meta-group><custom-meta><meta-name>version</meta-name><meta-value>1.0.0.25070</meta-value></custom-meta><custom-meta><meta-name>structure-time</meta-name><meta-value>2026-05-28T13:07:30</meta-value></custom-meta><custom-meta><meta-name>word-source</meta-name><meta-value>FX</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p specific-use="noneIndent">接收日期：2026-03-01</p><p>常染色体显性遗传性多囊肾病（autosomal dominant polycystic kidney disease，ADPKD）是最常见的成人遗传性肾脏疾病，其发病率在1/1 000~1/400<sup>［<xref ref-type="bibr" rid="R1">1</xref>］</sup>，也是继慢性肾小球肾炎、糖尿病肾病、肾良性小动脉硬化症后第四位导致终末期肾脏病（end-stage renal disease，ESRD）的疾病。ADPKD以不断进展的肾脏实质多发囊肿为主要特征，临床常伴有尿路感染（urinary tract infection， UTI）、疼痛、血尿等症状，随着疾病进展，患者的肾功能进行性衰退，最终发展至终末期肾病<sup>［<xref ref-type="bibr" rid="R2">2</xref>］</sup>。UTI是ADPKD的常见并发症，约30%~50%的ADPKD患者一生中至少发生1次UTI，不仅使患者感到不适，更与患者的肾功能损伤密切相关。随着抗生素的使用，耐药菌不断增多，使UTI的治疗复杂化。识别ADPKD患者中的UTI高危人群，对发生UTI的患者及时进行抗感染治疗，可改善患者预后，延缓病程进展。目前，有关ADPKD患者发生UTI危险因素的研究较为少见。该研究通过回顾性分析ADPKD患者并发UTI的临床特征与病原体分布，探索可能导致ADPKD患者发生UTI的危险因素，以期对合并有高危因素的ADPKD患者给予早期临床干预指导，减少UTI事件的发生。</p><sec id="s1"><label>1</label><title>材料与方法</title><sec id="s1a"><label>1.1</label><title>病例资料</title><p specific-use="noneIndent">收集2018年3月—2024年3月就诊于安徽医科大学第一附属医院高新院区肾脏内科的ADPKD患者，本研究为回顾性分析，经本院医学伦理委员会批准免除患者知情同意后进行。</p></sec><sec id="s1b"><label>1.2</label><title>纳入和排除标准</title><p specific-use="noneIndent">ADPKD患者的肾脏超声影像特点<sup> ［<xref ref-type="bibr" rid="R3">3</xref>］</sup>：15~39岁，双侧肾脏囊肿数≥3个；40~59岁，每侧肾脏囊肿数≥2个；≥60岁，每侧肾脏囊肿数≥4个。</p><p>纳入标准：① 年龄18岁及以上；② 临床资料完整无残缺。排除标准：① 合并其他系统感染者；② 合并血液、免疫系统疾病者；③ 有院外抗生素使用史。</p></sec><sec id="s1c"><label>1.3</label><title>一般资料项目与分组</title><p specific-use="noneIndent">回顾性分析患者的临床资料，包括：患者性别、年龄及检验指标包括血液常规（白细胞计数、中性粒细胞百分比、血红蛋白、血小板计数）、尿常规（尿白细胞计数、尿红细胞计数、亚硝酸盐还原试验、白细胞酯酶试验）、肝功能、血脂、肾功能、血电解质、血糖、甲状旁腺激素、钙磷乘积、铁代谢相关指标、C反应蛋白（C-reactive protein，CRP）等清洁中段尿液细菌培养及药物敏感性分析、泌尿系统超声或其他泌尿系影像学检查等资料。将诊断发生UTI的ADPKD患者纳入研究组，未发生UTI的患者纳入对照组。</p></sec><sec id="s1d"><label>1.4</label><title>统计学处理</title><p specific-use="noneIndent">采用SPSS 27.0统计学软件对数据进行处理，正态分布计量资料采用<inline-formula><alternatives><mml:math id="M1"><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>±</mml:mo><mml:mi>s</mml:mi></mml:math><graphic specific-use="big" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-M001.jpg"><?fx-imagestate width="7.53533268" height="2.62466669"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-M001c.jpg"><?fx-imagestate width="7.53533268" height="2.62466669"?></graphic></alternatives></inline-formula>表示，组间比较用<italic>t</italic>检验；偏态分布资料采用<italic>M</italic>（<italic>P</italic><sub>25</sub><italic>，P</italic><sub>75</sub>）表示，组间比较用Mann-Whitney <italic>U</italic>检验；计数资料以<italic>n</italic>（%）表示。单因素分析有统计学意义则行多因素Logistic回归分析，<italic>P</italic>&lt;0.05为差异有统计学意义。</p></sec></sec><sec id="s2"><label>2</label><title>结果</title><sec id="s2a"><label>2.1</label><title>研究组与对照组的人口学特征</title><p specific-use="noneIndent">305名诊断ADPKD的住院患者，因合并其他系统感染不符合纳入标准排除34例，因缺少相应检验资料排除27例，最终共纳入244例ADPKD患者。研究组有138例ADPKD患者合并UTI，其中男性41例（29.7 %），女性97例（70.3%）。对照组有106例非UTI患者，其中男性54例（50.9%），女性52例（49.1%）。</p></sec><sec id="s2b"><label>2.2</label><title>ADPKD患者发生UTI的病原体分布情况</title><p specific-use="noneIndent">纳入138例ADPKD并发UTI患者，共检出105株病原体，以细菌最多见（99株，94.3%），其中革兰染色阴性菌（79株，75.2%），包括大肠埃希菌（49株，46.7%）、肺炎克雷伯杆菌（10株，9.5%）、奇异变形杆菌（4株，3.8%）、阴沟肠杆菌（3株，2.9%）、产气肠杆菌（2株，1.9%）、豚鼠气单胞菌（2株，1.9%）、恶臭假单胞菌（2株，1.9%）、铜绿假单胞菌（2株，1.9%）、其他少见细菌（5株，4.5%）；革兰染色阳性菌（20株，19.0%），包括粪肠球菌（11株，10.5%）、表皮葡萄球菌（3株，2.9%）、无乳链球菌（3株，2.9%）、其他少见细菌（3株，2.9%）。其次为真菌（6株，5.7%），包括光滑假丝酵母菌（3株，2.9%）、热带假丝酵母菌（2株，1.9%） 、克柔假丝酵母菌（1株，0.9%）。</p></sec><sec id="s2c"><label>2.3</label><title>ADPKD患者发生UTI的主要革兰染色细菌药敏情况</title><p specific-use="noneIndent">大肠埃希菌是检出率最高的革兰染色阴性菌，对左氧氟沙星、氨苄西林、哌拉西林、头孢他啶、头孢吡肟、头孢曲松、复方新诺明耐药率较高，对头孢哌酮舒巴坦、哌拉西林他唑巴坦、亚胺培南敏感性较强，41株细菌中有21株超广谱β-内酰胺酶阳性；肺炎克雷伯菌中耐药菌少见，未见对头孢哌酮舒巴坦、哌拉西林他唑巴坦、亚胺培南耐药菌株（<xref ref-type="table" rid="T1">表1</xref>）。革兰染色阳性细菌中粪肠球菌检出率最高，对于四环素、环丙沙星及左氧氟沙星耐药率较高，见<xref ref-type="table" rid="T2">表2</xref>。</p><table-wrap id="T1"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.04.001.T001</object-id><label>表1</label><caption><p>ADPKD合并UTI患者尿液中常见革兰染色阴性细菌药敏结果</p></caption><abstract abstract-type="caption" xml:lang="en"><label>Tab.1</label><title>Antibiotic susceptibility test results of common Gram-negative bacteria in the urine of ADPKD patients with UTI</title></abstract><alternatives><table id="Table1"><thead><tr><th align="left" rowspan="2" style="border-top:solid;border-bottom:solid;">Antibiotic type</th><th align="center" colspan="3" style="border-top:solid;border-bottom:solid;"><italic>Escherichia coli</italic></th><th align="center" colspan="3" style="border-top:solid;border-bottom:solid;"><italic>Klebsiella pneumoniae</italic></th></tr><tr><th align="center" style="border-bottom:solid;">Sensitive</th><th align="center" style="border-bottom:solid;">Resistant</th><th align="center" style="border-bottom:solid;">Resistance rate</th><th align="center" style="border-bottom:solid;">Sensitive</th><th align="center" style="border-bottom:solid;">Resistant</th><th align="center" style="border-bottom:solid;">Resistance rate</th></tr></thead><tbody><tr align="center"><td align="left">Ampicillin</td><td align="center">7/49</td><td align="center">32/49</td><td align="center">-</td><td align="center">-</td><td align="center">1/10</td><td align="center">-</td></tr><tr align="center"><td align="left">Piperacillin/tazobactam sodium</td><td align="center">42/49</td><td align="center">0</td><td align="center">-</td><td align="center">10/10</td><td align="center">0</td><td align="center">0</td></tr><tr align="center"><td align="left">Cefoperazone/Sulbactam</td><td align="center">32/49</td><td align="center">0</td><td align="center">-</td><td align="center">9/10</td><td align="center">0</td><td align="center">0</td></tr><tr align="center"><td align="left">Cefotetan</td><td align="center">35/49</td><td align="center">-</td><td align="center">-</td><td align="center">10/10</td><td align="center">0</td><td align="center">0</td></tr><tr align="center"><td align="left">Ceftazidime</td><td align="center">24/49</td><td align="center">10/49</td><td align="center">-</td><td align="center">9/10</td><td align="center">0</td><td align="center">0</td></tr><tr align="center"><td align="left">Ceftriaxone</td><td align="center">26/49</td><td align="center">22/49</td><td align="center">44.9%</td><td align="center">8/10</td><td align="center">2/10</td><td align="center">20%</td></tr><tr align="center"><td align="left">Imipenem</td><td align="center">48/49</td><td align="center">1/49</td><td align="center">2.0%</td><td align="center">10/10</td><td align="center">0</td><td align="center">0</td></tr><tr align="center"><td align="left">Ciprofloxacin</td><td align="center">26/49</td><td align="center">23/49</td><td align="center">46.9%</td><td align="center">5/10</td><td align="center">4/10</td><td align="center">40%</td></tr><tr align="center"><td align="left">Levofloxacin</td><td align="center">20/49</td><td align="center">19/49</td><td align="center">38.8%</td><td align="center">5/10</td><td align="center">3/10</td><td align="center">30%</td></tr><tr align="center"><td align="left">Amikacin</td><td align="center">47/49</td><td align="center">2/49</td><td align="center">4.1%</td><td align="center">10/10</td><td align="center">0</td><td align="center">0</td></tr><tr align="center"><td align="left">Cefepime</td><td align="center">38/49</td><td align="center">11/49</td><td align="center">22.4%</td><td align="center">9/10</td><td align="center">0</td><td align="center">0</td></tr><tr align="center"><td align="left">Cotrimoxazole</td><td align="center">32/49</td><td align="center">17/49</td><td align="center">34.6%</td><td align="center">7/10</td><td align="center">3/10</td><td align="center">30%</td></tr><tr align="center"><td align="left" style="border-bottom:solid;">Piperacillin</td><td align="center" style="border-bottom:solid;">17/49</td><td align="center" style="border-bottom:solid;">25/49</td><td align="center" style="border-bottom:solid;">-</td><td align="center" style="border-bottom:solid;">5/10</td><td align="center" style="border-bottom:solid;">2/10</td><td align="center" style="border-bottom:solid;">-</td></tr></tbody></table><graphic specific-use="big" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-T001.jpg"><?fx-imagestate width="169.79997253" height="71.10000610"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-T001c.jpg"><?fx-imagestate width="169.79997253" height="71.10000610"?></graphic></alternatives><table-wrap-foot><fn><p>- ： means not detected.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.04.001.T002</object-id><label>表2</label><caption><p>ADPKD合并UTI患者尿液中常见革兰染色阳性细菌药敏结果</p></caption><abstract abstract-type="caption" xml:lang="en"><label>Tab.2</label><title>Antibiotic susceptibility test results of common Gram-positive bacteria in the urine of ADPKD patients with UTI</title></abstract><alternatives><table id="Table2"><thead><tr><th align="left" style="border-top:solid;border-bottom:solid;">Antibiotic type</th><th align="center" style="border-top:solid;border-bottom:solid;">Sensitive</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>Enterococcus faecalis </italic>resistant</th><th align="center" style="border-top:solid;border-bottom:solid;">Resistance rate</th></tr></thead><tbody><tr align="center"><td align="left">Penicillin</td><td align="center">10/11</td><td align="center">1/11</td><td align="center">9.1%</td></tr><tr align="center"><td align="left">Ciprofloxacin</td><td align="center">8/11</td><td align="center">3/11</td><td align="center">27.3%</td></tr><tr align="center"><td align="left">Levofloxacin</td><td align="center">8/11</td><td align="center">3/11</td><td align="center">27.3%</td></tr><tr align="center"><td align="left">Linezolid</td><td align="center">9/11</td><td align="center">0</td><td align="center">-</td></tr><tr align="center"><td align="left">Tetracycline</td><td align="center">4/11</td><td align="center">7/11</td><td align="center">63.6%</td></tr><tr align="center"><td align="left">Vancomycin</td><td align="center">11/11</td><td align="center">0</td><td align="center">0</td></tr><tr align="center"><td align="left">Ampicillin</td><td align="center">11/11</td><td align="center">0</td><td align="center">0</td></tr><tr align="center"><td align="left" style="border-bottom:solid;">Tigecycline</td><td align="center" style="border-bottom:solid;">11/11</td><td align="center" style="border-bottom:solid;">0</td><td align="center" style="border-bottom:solid;">0</td></tr></tbody></table><graphic specific-use="big" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-T002.jpg"><?fx-imagestate width="81.19583130" height="45.99209595"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-T002c.jpg"><?fx-imagestate width="81.19583130" height="45.99209595"?></graphic></alternatives><table-wrap-foot><fn><p>-： means not detected.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2d"><label>2.4</label><title>研究组与对照组临床资料对比</title><p specific-use="noneIndent">将收集到的数据整理后进行单因素方差分析，研究组与对照组在性别、UTI既往史、血总蛋白、CRP、尿红细胞、尿白细胞增多、血钠、血钙、血清铁、转铁饱和度方面差异有统计学意义（<italic>P</italic>&lt;0.05），其余指标差异无统计学意义。见<xref ref-type="table" rid="T3">表3</xref>。</p><table-wrap id="T3"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.04.001.T003</object-id><label>表3</label><caption><p>ADPKD患者发生UTI的单因素分析 ［<italic>n</italic>（%）， <italic>M</italic>（<italic>P</italic><sub>25</sub><italic>，P</italic><sub>75</sub>）， <inline-formula><alternatives><mml:math id="M2"><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math><graphic specific-use="big" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-M002.jpg"><?fx-imagestate width="1.35466671" height="2.03200006"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-M002c.jpg"><?fx-imagestate width="1.35466671" height="2.03200006"?></graphic></alternatives></inline-formula>±<italic>s</italic>］</p></caption><abstract abstract-type="caption" xml:lang="en"><label>Tab.3</label><title>Univariate analysis of UTI in patients with ADPKD ［<italic>n</italic>（%）， <italic>M</italic>（<italic>P</italic><sub>25</sub><italic>，P</italic><sub>75</sub>）， <inline-formula><alternatives><mml:math id="M3"><mml:mover accent="true"><mml:mi>x</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math><graphic specific-use="big" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-M002.jpg"><?fx-imagestate width="1.35466671" height="2.03200006"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-M002c.jpg"><?fx-imagestate width="1.35466671" height="2.03200006"?></graphic></alternatives></inline-formula>±<italic>s</italic>］</title></abstract><alternatives><table id="Table3"><thead><tr><th align="left" style="border-top:solid;border-bottom:solid;">Subject</th><th align="center" style="border-top:solid;border-bottom:solid;">Control group （<italic>n</italic>=106）</th><th align="center" style="border-top:solid;border-bottom:solid;">Research group （<italic>n</italic>=138）</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>t/Z/χ²</italic>value</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>P </italic>value</th></tr></thead><tbody><tr align="center"><td align="left">Age （years）</td><td align="center">52.50 （47.00，58.00）</td><td align="center">52.00 （48.00，56.25）</td><td align="center">-0.381</td><td align="center">0.703</td></tr><tr align="center"><td align="left">Gender</td><td align="left"/><td align="left"/><td align="center">10.493</td><td align="center">0.001</td></tr><tr align="center"><td align="left" style="text-indent:1em;">Male</td><td align="center">54 （50.9）</td><td align="center">41 （29.7）</td><td align="left" rowspan="2"/><td align="left" rowspan="2"/></tr><tr align="center"><td align="left" style="text-indent:1em;">Female</td><td align="center">52 （49.1）</td><td align="center">97 （70.3）</td></tr><tr align="center"><td align="left">Previous history of UTI</td><td align="center">35 （33.0）</td><td align="center">73 （52.9）</td><td align="center">8.815</td><td align="center">0.003</td></tr><tr align="center"><td align="left">Urinary tract malformation</td><td align="center">60 （56.6）</td><td align="center">71 （51.4）</td><td align="center">0.450</td><td align="center">0.502</td></tr><tr align="center"><td align="left">WBC （×10<sup>9</sup>/L）</td><td align="center">5.61 （4.42，7.02）</td><td align="center">5.56 （4.40，6.90）</td><td align="center">-0.555</td><td align="center">0.579</td></tr><tr align="center"><td align="left">Neutrophil percentage （%）</td><td align="center">69.80 （66.27，74.90）</td><td align="center">73.30 （67.25，80.60）</td><td align="center">-2.633</td><td align="center">0.008</td></tr><tr align="center"><td align="left">Hemoglobin （g/L）</td><td align="center">103.26±24.83</td><td align="center">100.88±21.08</td><td align="center">0.792</td><td align="center">0.429</td></tr><tr align="center"><td align="left">Urine leukocytosis</td><td align="center">51 （48.1）</td><td align="center">101 （74.3）</td><td align="center">16.443</td><td align="center">0.001</td></tr><tr align="center"><td align="left">Urine erythrocyte （/HP）</td><td align="center">7.00 （2.00，21.00）</td><td align="center">22.00 （6.00，288.00）</td><td align="center">-4.764</td><td align="center">0.001</td></tr><tr align="center"><td align="left">Total serum protein （g/L）</td><td align="center">66.75 （61.68，71.23）</td><td align="center">69.10 （64.95，72.50）</td><td align="center">-2.384</td><td align="center">0.017</td></tr><tr align="center"><td align="left">Serum albumin（g/L）</td><td align="center">38.64±5.38</td><td align="center">38.15±4.87</td><td align="center">0.731</td><td align="center">0.465</td></tr><tr align="center"><td align="left">ALT （U/L）</td><td align="center">13.50 （9.00，18.25）</td><td align="center">13.00 （9.00，21.00）</td><td align="center">-0.172</td><td align="center">0.863</td></tr><tr align="center"><td align="left">AST （U/L）</td><td align="center">17.50 （14.00，22.25）</td><td align="center">20.00 （15.75，25.00）</td><td align="center">-2.163</td><td align="center">0.031</td></tr><tr align="center"><td align="left">CRP （mg/L）</td><td align="center">2.18 （0.75，6.88）</td><td align="center">5.70 （1.20，33.81）</td><td align="center">-3.286</td><td align="center">0.001</td></tr><tr align="center"><td align="left">Serum urea nitrogen （mmol/L）</td><td align="center">19.68 （13.32，26.30）</td><td align="center">19.60 （11.40，25.79）</td><td align="center">-0.609</td><td align="center">0.542</td></tr><tr align="center"><td align="left">Serum creatinine （μmol/L）</td><td align="center">559.00 （297.55，914.25）</td><td align="center">507.8 （161.63，911.33）</td><td align="center">-1.035</td><td align="center">0.301</td></tr><tr align="center"><td align="left">Serum uric acid （μmol/L）</td><td align="center">430.50 （354.25，520.5）</td><td align="center">429.50 （343.75，513.25）</td><td align="center">-0.574</td><td align="center">0.566</td></tr><tr align="center"><td align="left">eGFR ［mL/（min·1.73 m<sup>2</sup>）］</td><td align="center">8.00 （5.00，17.50）</td><td align="center">8.00 （4.00，26.00）</td><td align="center">-0.454</td><td align="center">0.650</td></tr><tr align="center"><td align="left">Serum potassium ion （mmol/L）</td><td align="center">3.98 （3.64，4.48）</td><td align="center">4.00 （3.62，4.47）</td><td align="center">-0.020</td><td align="center">0.984</td></tr><tr align="center"><td align="left">Serum sodium ion （mmol/L）</td><td align="center">140.30 （138.70，141.90）</td><td align="center">139.40 （137.70，141.00）</td><td align="center">-3.286</td><td align="center">0.001</td></tr><tr align="center"><td align="left">Serum chloride ion （mmol/L）</td><td align="center">106.40 （103.00，110.20）</td><td align="center">105.70 （102.90，109.80）</td><td align="center">-0.870</td><td align="center">0.384</td></tr><tr align="center"><td align="left">Serum bicarbonate ion （mmol/L）</td><td align="center">22.15 （18.78，25.13）</td><td align="center">21.50 （18.50，23.60）</td><td align="center">-1.073</td><td align="center">0.283</td></tr><tr align="center"><td align="left">Serum calcium ion （mmol/L）</td><td align="center">2.18 （2.03，2.27）</td><td align="center">2.22 （2.09，2.31）</td><td align="center">-2.015</td><td align="center">0.041</td></tr><tr align="center"><td align="left">Serum phosphorus ion （mmol/L）</td><td align="center">1.58 （1.31，1.89）</td><td align="center">1.54 （1.20，1.82）</td><td align="center">-1.441</td><td align="center">0.150</td></tr><tr align="center"><td align="left">Calcium and phosphorus product</td><td align="center">3.29 （2.87，3.95）</td><td align="center">3.27 （2.73，4.23）</td><td align="center">-0.729</td><td align="center">0.466</td></tr><tr align="center"><td align="left">Total cholesterol（mmol/L）</td><td align="center">4.01±0.88</td><td align="center">3.89±1.07</td><td align="center">-1.410</td><td align="center">0.159</td></tr><tr align="center"><td align="left">Triglycerides （mmol/L）</td><td align="center">1.16 （0.83，1.70）</td><td align="center">1.16 （0.81，1.56）</td><td align="center">-0.172</td><td align="center">0.863</td></tr><tr align="center"><td align="left">Fasting blood glucose （mmol/L）</td><td align="center">4.87 （4.30，5.30）</td><td align="center">4.74 （4.27，5.43）</td><td align="center">-0.421</td><td align="center">0.673</td></tr><tr align="center"><td align="left">Parathyroid hormone （pg/L）</td><td align="center">193.00 （104.25，339.50）</td><td align="center">179.00 （70.40，314.00）</td><td align="center">-1.339</td><td align="center">0.180</td></tr><tr align="center"><td align="left">Serum iron ion （μmol/L）</td><td align="center">10.75 （7.50，14.13）</td><td align="center">9.20 （6.30，12.10）</td><td align="center">-3.168</td><td align="center">0.002</td></tr><tr align="center"><td align="left">Serum ferritin （mmol/L）</td><td align="center">138.00 （73.75，290.75）</td><td align="center">167.00 （91.75，327.00）</td><td align="center">-1.324</td><td align="center">0.186</td></tr><tr align="center"><td align="left">Transferrin saturation （%）</td><td align="center">22.72 （16.96，31.67）</td><td align="center">20.00 （12.43，29.23）</td><td align="center">-2.726</td><td align="center">0.006</td></tr><tr align="center"><td align="left" style="border-bottom:solid;">TIBC （μmol/L）</td><td align="center" style="border-bottom:solid;">41.89 （35.97，46.98）</td><td align="center" style="border-bottom:solid;">41.11 （34.23，46.35）</td><td align="center" style="border-bottom:solid;">-0.893</td><td align="center" style="border-bottom:solid;">0.372</td></tr></tbody></table><graphic specific-use="big" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-T003.jpg"><?fx-imagestate width="169.79998779" height="165.59907532"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-T003c.jpg"><?fx-imagestate width="169.79998779" height="165.59907532"?></graphic></alternatives></table-wrap></sec><sec id="s2e"><label>2.5</label><title>ADPKD合并UTI影响因素的多因素二元Logistic回归分析</title><p specific-use="noneIndent">将单因素方差分析中有显著统计学差异的变量带入多因素二元Logistic回归分析，包括：性别、UTI既往史、血总蛋白、CRP、尿红细胞、尿白细胞增多、血钠、血钙、血清铁、转铁饱和度。结果显示，ADPKD患者的女性性别、UTI既往史、尿白细胞增多、中性粒细胞百分比升高、CRP升高、血钙升高是发生UTI的危险因素，见图<xref ref-type="fig" rid="F1">1</xref>、<xref ref-type="fig" rid="F2">2</xref>和<xref ref-type="table" rid="T4">表4</xref>。</p><fig position="float" id="F1"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.04.001.F001</object-id><label>图1</label><caption><title>危险因素的ROC曲线</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig.1</label><title>ROC curve for risk factors</title></abstract><alternatives><graphic specific-use="print" xlink:href="media/117D002D-F905-4e5a-9A2E-ADCEE0779016-F001.eps" id="Graphic1"><?fx-imagestate width="69.84999847" height="67.73333740"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-F001.jpg"><?fx-imagestate width="69.84999847" height="67.73333740"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-F001c.jpg"><?fx-imagestate width="69.84999847" height="67.73333740"?></graphic></alternatives></fig><fig position="float" id="F2"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.04.001.F002</object-id><label>图2</label><caption><title>模型的ROC曲线</title></caption><abstract abstract-type="caption" xml:lang="en"><label>Fig.2</label><title>ROC curve for model</title></abstract><alternatives><graphic specific-use="print" xlink:href="media/117D002D-F905-4e5a-9A2E-ADCEE0779016-F002.eps" id="Graphic2"><?fx-imagestate width="66.67500305" height="62.08888626"?></graphic><graphic specific-use="big" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-F002.jpg"><?fx-imagestate width="66.67500305" height="62.08888626"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-F002c.jpg"><?fx-imagestate width="66.67500305" height="62.08888626"?></graphic></alternatives></fig><table-wrap id="T4"><object-id pub-id-type="doi">10.19405/j.cnki.issn1000–1492.2026.04.001.T004</object-id><label>表4</label><caption><p>ADPKD患者发生UTI的多因素二元Logistic回归分析</p></caption><abstract abstract-type="caption" xml:lang="en"><label>Tab.4</label><title>Multivariate binary Logistic regression analysis of UTI in ADPKD patients</title></abstract><alternatives><table id="Table4"><thead><tr><th align="left" style="border-top:solid;border-bottom:solid;">Influencing factor</th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>β</italic></th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>SE</italic></th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>OR</italic></th><th align="center" style="border-top:solid;border-bottom:solid;">95% <italic>CI</italic></th><th align="center" style="border-top:solid;border-bottom:solid;"><italic>P</italic></th></tr></thead><tbody><tr align="center"><td align="left">Gender</td><td align="center">0.805</td><td align="center">0.277</td><td align="center">2.236</td><td align="center">1.298-3.851</td><td align="center">0.004</td></tr><tr align="center"><td align="left">Previous history of UTI</td><td align="center">0.868</td><td align="center">0.275</td><td align="center">2.383</td><td align="center">1.389-4.088</td><td align="center">0.002</td></tr><tr align="center"><td align="left">CRP</td><td align="center">0.011</td><td align="center">0.004</td><td align="center">1.011</td><td align="center">1.003-1.019</td><td align="center">0.007</td></tr><tr align="center"><td align="left">Urine erythrocyte</td><td align="center">0.000</td><td align="center">0.000</td><td align="center">1.000</td><td align="center">1.000-1.000</td><td align="center">0.656</td></tr><tr align="center"><td align="left">Urine leukocytosis</td><td align="center">1.003</td><td align="center">0.279</td><td align="center">2.726</td><td align="center">1.579-4.708</td><td align="center">0.001</td></tr><tr align="center"><td align="left">Neutrophil percentage</td><td align="center">0.039</td><td align="center">0.015</td><td align="center">1.040</td><td align="center">1.009-1.072</td><td align="center">0.010</td></tr><tr align="center"><td align="left">Serum sodium ion</td><td align="center">-0.001</td><td align="center">0.001</td><td align="center">0.999</td><td align="center">0.997-1.001</td><td align="center">0.406</td></tr><tr align="center"><td align="left">Serum calcium ion</td><td align="center">1.479</td><td align="center">0.655</td><td align="center">4.389</td><td align="center">1.217-15.832</td><td align="center">0.024</td></tr><tr align="center"><td align="left">Serum iron ion</td><td align="center">-0.009</td><td align="center">0.013</td><td align="center">0.991</td><td align="center">0.966-1.016</td><td align="center">0.484</td></tr><tr align="center"><td align="left" style="border-bottom:solid;">Transferrin saturation</td><td align="center" style="border-bottom:solid;">-0.005</td><td align="center" style="border-bottom:solid;">0.012</td><td align="center" style="border-bottom:solid;">0.935</td><td align="center" style="border-bottom:solid;">0.962-1.024</td><td align="center" style="border-bottom:solid;">0.566</td></tr></tbody></table><graphic specific-use="big" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-T004.jpg"><?fx-imagestate width="81.19583130" height="49.43399811"?></graphic><graphic specific-use="small" xlink:href="alternativeImage/117D002D-F905-4e5a-9A2E-ADCEE0779016-T004c.jpg"><?fx-imagestate width="81.19583130" height="49.43399811"?></graphic></alternatives></table-wrap></sec></sec><sec id="s3"><label>3</label><title>讨论</title><p>ADPKD是成人最常见的遗传性肾脏疾病，随着病情进展肾脏体积增大，肾功能进行性衰退，通常在患者60岁左右发展至ESRD<sup>［<xref ref-type="bibr" rid="R4">4</xref>］</sup>。UTI是ADPKD的主要并发症，与ADPKD患者的肾功能损伤有关。UTI若不能及时控制，则可能使病原体侵入血液向全身扩散，引发脓毒症等能够危及患者生命的严重并发症<sup>［<xref ref-type="bibr" rid="R5">5</xref>］</sup>，因此应重视ADPKD患者并发UTI的情况。</p><p>UTI最常见的病原体为大肠埃希菌<sup>［<xref ref-type="bibr" rid="R6">6</xref>］</sup>。在本次研究中，研究组共检出以大肠埃希菌为主的革兰染色阴性细菌79株，以粪肠球菌为主的革兰染色阳性菌20株，真菌6株。研究组患者UTI的病原菌以大肠埃希菌最为多见（49株），这与其他种类的UTI的病原菌分布相近<sup>［<xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R8">8</xref>］</sup>，临床患者诊断UTI进行经验性治疗时应首先考虑此类可能。检出的革兰染色阳性细菌中未发现对万古霉素、替加环素及利奈唑胺耐药菌株。研究组中革兰染色阳性细菌与革兰染色阴性细菌的耐药谱有所不同，主要是两类细菌细胞的不同的结构特性所造成的。研究组患者还有混合感染的情况存在，在临床治疗时应重视这一病原学特征。检出的大肠埃希菌多是多药耐药菌，对于环丙沙星等喹诺酮类药物以及氨苄西林、哌拉西林等β-内酰胺类药物等多种抗生素耐药率较高，在临床治疗中需严格控制抗生素使用。</p><p>研究组与对照组在性别、UTI既往史、CRP、尿红细胞、尿白细胞增多、中性粒细胞百分比、血钠、血钙、血清铁、转铁饱和度方面存在统计学差异（<italic>P</italic>&lt;0.05），进一步分析发现ADPKD患者的女性、UTI既往史、尿白细胞增多、中性粒细胞百分比升高、CRP升高、血钙升高是发生UTI的危险因素。女性患者尿道短而宽，同时尿道口、肛门及阴道口位置接近，若日常行为与护理不当，细菌易由尿道口逆行进入尿路引发UTI。有研究<sup>［<xref ref-type="bibr" rid="R9">9</xref>］</sup>指出，绝经后女性发生UTI的风险较育龄期女性有所升高。女性尿路中乳酸杆菌能够维持酸性环境，其损伤有利于致病性尿路病原体的定植。绝经期女性的雌激素水平降低会使得泌尿生殖系统的微生物菌群状态，使得尿路乳酸杆菌减少，同时还会直接影响机体泌尿系统的组织细胞发生生理改变，更容易引发UTI。</p><p>研究组中有UTI病史的患者的比例高于对照组。UTI的发生是由病原体的致病力、易感因素与机体的防御功能等多种因素共同作用导致。当有UTI病史的ADPKD患者出现发热等症状时，应警惕发生UTI的可能。</p><p>尿白细胞增多与ADPKD患者发生UTI之间正相关（<italic>OR</italic>=2.726，<italic>P</italic>=0.001）。在一项有关尿液成分对于UTI诊断的研究中，患者有无脓尿可协助诊断UTI（敏感度0.92，95%<italic>CI</italic>：0.90~0.94，特异度0.43，95%<italic>CI</italic>：0.42~0.45）<sup>［<xref ref-type="bibr" rid="R10">10</xref>］</sup>。</p><p>CRP升高与ADPKD患者发生UTI之间正相关。CRP是一种非特异的炎症标志物，能够与补体相互作用，激活机体对感染的防御作用，可用于协助诊断UTI的发生<sup>［<xref ref-type="bibr" rid="R11">11</xref>］</sup>。而研究组中性粒细胞百分比较对照组升高，中性粒细胞百分比升高多见于急性感染、炎症等情况，有助于ADPKD患者发生UTI的诊断。同时分析发现ADPKD患者的血钙升高是发生UTI的危险因素，当一些患者长期或重度血钙升高时，会形成含钙尿路结石，当结石阻塞尿路，梗阻部位之上的尿路存在细菌时，则可能诱发UTI。</p></sec></body><back><ref-list><title>参考文献</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Bergmann</surname><given-names>C</given-names></name>， <name name-style="eastern"><surname>Guay-Woodford</surname><given-names>L M</given-names></name>， <name name-style="eastern"><surname>Harris</surname><given-names>P C</given-names></name>， <etal>et al</etal></person-group>. <article-title>Polycystic kidney disease</article-title>［J］. <source>Nat Rev Dis Primers</source>， <year>2018</year>， <volume>4</volume>： <fpage>50</fpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1038/s41572-018-0047-y">10.1038/s41572-018-0047-y</ext-link></comment>.</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Malekshahabi</surname><given-names>T</given-names></name>， <name name-style="eastern"><surname>Khoshdel Rad</surname><given-names>N</given-names></name>， <name name-style="eastern"><surname>Serra</surname><given-names>A L</given-names></name>， <etal>et al</etal></person-group>. <article-title>Autosomal dominant polycystic kidney disease： disrupted pathways and potential therapeutic interventions</article-title>［J］. <source>J Cell Physiol</source>， <year>2019</year>， <volume>234</volume>（<issue>8</issue>）： <fpage>12451</fpage>-<lpage>70</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1002/jcp.28094">10.1002/jcp.28094</ext-link></comment>.</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Torres</surname><given-names>V E</given-names></name>， <name name-style="eastern"><surname>Ahn</surname><given-names>C</given-names></name>， <name name-style="eastern"><surname>Barten</surname><given-names>T R M</given-names></name>， <etal>et al</etal></person-group>. <article-title>KDIGO 2025 clinical practice guideline for the evaluation， management， and treatment of autosomal dominant polycystic kidney disease （ADPKD）： executive summary</article-title>［J］. <source>Kidney Int</source>， <year>2025</year>， <volume>107</volume>（<issue>2</issue>）： <fpage>234</fpage>-<lpage>54</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1016/j.kint.2024.07.010">10.1016/j.kint.2024.07.010</ext-link></comment>.</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Righini</surname><given-names>M</given-names></name>， <name name-style="eastern"><surname>Mancini</surname><given-names>R</given-names></name>， <name name-style="eastern"><surname>Busutti</surname><given-names>M</given-names></name>， <etal>et al</etal></person-group>. <article-title>Autosomal dominant polycystic kidney disease： extrarenal involvement</article-title>［J］. <source>Int J Mol Sci</source>， <year>2024</year>， <volume>25</volume>（<issue>5</issue>）： <fpage>2554</fpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.3390/ijms25052554">10.3390/ijms25052554</ext-link></comment>.</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Scotland</surname><given-names>K B</given-names></name>， <name name-style="eastern"><surname>Lo</surname><given-names>J</given-names></name>， <name name-style="eastern"><surname>Grgic</surname><given-names>T</given-names></name>， <etal>et al</etal></person-group>. <article-title>Ureteral stent-associated infection and sepsis： pathogenesis and prevention： a review</article-title>［J］. <source>Biofouling</source>， <year>2019</year>， <volume>35</volume>（<issue>1</issue>）： <fpage>117</fpage>-<lpage>27</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1080/08927014.2018.1562549">10.1080/08927014.2 018.1562549</ext-link></comment>.</mixed-citation></ref><ref id="R6"><label>6</label><citation-alternatives><mixed-citation publication-type="journal" publication-format="print"><person-group><string-name>罗晓妹</string-name>， <string-name>张　培</string-name>， <string-name>齐向明</string-name>， <etal>等</etal></person-group>. <article-title>持续不卧床腹膜透析患者发生泌尿道感染的危险因素及病原学特点</article-title>［J］. <source>安徽医科大学学报</source>， <year>2021</year>， <volume>56</volume>（<issue>10</issue>）： <fpage>1656</fpage>-<lpage>60</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.19405/j.cnki.issn1000-1492.2021.10.029">10.19405/j.cnki.issn1000-1492.2021.10.029</ext-link></comment>.</mixed-citation><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Luo</surname><given-names>X M</given-names></name>， <name name-style="eastern"><surname>Zhang</surname><given-names>P</given-names></name>， <name name-style="eastern"><surname>Qi</surname><given-names>X M</given-names></name>， <etal>et al</etal></person-group>. <article-title>Risk factors and etiological characteristics of urinary tract infection in continuous ambulatory peritoneal dialysis patients</article-title>［J］. <source>Acta Univ Med Anhui</source>， <year>2021</year>， <volume>56</volume>（<issue>10</issue>）： <fpage>1656</fpage>-<lpage>60</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.19405/j.cnki.issn1000-1492.2021.10.029">10.19405/j.cnki.issn1000-1492. 2021. 10.029</ext-link></comment>.</mixed-citation></citation-alternatives></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Liu</surname><given-names>J</given-names></name>， <name name-style="eastern"><surname>Hao</surname><given-names>X</given-names></name>， <name name-style="eastern"><surname>Shang</surname><given-names>X</given-names></name>， <etal>et al</etal></person-group>. <article-title>Incidence and risk factors of urinary tract infection in hospitalized patients with spinal cord injury in a hospital of China</article-title>［J］. <source>Sci Rep</source>， <year>2024</year>， <volume>14</volume>： <fpage>3579</fpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1038/s41598-024-54234-2">10.1038/s41598-024-54234-2</ext-link></comment>.</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>de Souza</surname><given-names>H D</given-names></name>， <name name-style="eastern"><surname>Diório</surname><given-names>G R M</given-names></name>， <name name-style="eastern"><surname>Peres</surname><given-names>S V</given-names></name>， <etal>et al</etal></person-group>. <article-title>Bacterial profile and prevalence of urinary tract infections in pregnant women in Latin America： a systematic review and meta-analysis</article-title>［J］. <source>BMC Pregnancy Childbirth</source>， <year>2023</year>， <volume>23</volume>： <fpage>774</fpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1186/s12884-023-06060-z">10.1186/s12884-023-06060-z</ext-link></comment>.</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Komesu</surname><given-names>Y M</given-names></name>， <name name-style="eastern"><surname>Dinwiddie</surname><given-names>D L</given-names></name>， <name name-style="eastern"><surname>Richter</surname><given-names>H E</given-names></name>， <etal>et al</etal></person-group>. <article-title>Defining the relationship between vaginal and urinary microbiomes</article-title>［J］. <source>Am J Obstet Gynecol</source>， <year>2020</year>， <volume>222</volume>（<issue>2</issue>）： <fpage>154.e1</fpage>-<lpage>154.e10</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1016/j.ajog.2019.08.011">10.1016/j.ajog.2019.08.011</ext-link></comment>.</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Advani</surname><given-names>S D</given-names></name>， <name name-style="eastern"><surname>North</surname><given-names>R</given-names></name>， <name name-style="eastern"><surname>Turner</surname><given-names>N A</given-names></name>， <etal>et al</etal></person-group>. <article-title>Performance of urinalysis parameters in predicting urinary tract infection： does one size fit all？</article-title>［J］. <source>Clin Infect Dis</source>， <year>2024</year>， <volume>79</volume>（<issue>3</issue>）： <fpage>600</fpage>-<lpage>3</lpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1093/cid/ciae230">10.1093/cid/ciae230</ext-link></comment>.</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal" publication-format="print" xml:lang="en"><person-group><name name-style="eastern"><surname>Hertz</surname><given-names>M A</given-names></name>， <name name-style="eastern"><surname>Johansen</surname><given-names>I S</given-names></name>， <name name-style="eastern"><surname>Rosenvinge</surname><given-names>F S</given-names></name>， <etal>et al</etal></person-group>. <article-title>The diagnostic accuracy of procalcitonin， soluble urokinase-type plasminogen activator receptors， and C-reactive protein in diagnosing urinary tract infections in the emergency department—a diagnostic accuracy study</article-title>［J］. <source>J Clin Med</source>， <year>2024</year>， <volume>13</volume>（<issue>6</issue>）： <fpage>1776</fpage>. <comment>doi：<ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.3390/jcm13061776">10.3390/jcm13061776</ext-link></comment>.</mixed-citation></ref></ref-list><fn-group><fn fn-type="other" specific-use="citation-format"><p>庞哲, 汪靓婧, 李大山, 等. 多囊肾病患者并发尿路感染的病原特征与危险因素分析[J]. 安徽医科大学学报, 2026, 61(04): 743-747.</p></fn><fn fn-type="other" specific-use="citation-format" xml:lang="en"><p>Pang Zhe, Wang Jingjing, Li Dashan, et al. Etiological characteristics and risk factors of urinary tract infection in patients with polycystic kidney disease[J]. Acta Universitatis Medicinalis Anhui, 2026, 61(04): 743-747.</p></fn></fn-group></back></article>